Skip to main content

Table 4 Summary estimates of the hazard ratio (HR) for the associations of high Ki-67 expression with overall survival (OS) of subtypes of lymphoma

From: Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

  Heterogeneity
Subtypes of lymphoma Number of studies Number of patients Pooled HR(95% CI) P value I2(%) P value
HL 2 162 1.511(0.524-4.358) 0.445 64.7% 0.092
NHL 22 3708 1.777(1.463-2.159) 0.000 74.3% 0.000
DLBCL (total) 11 2588 1.457(1.123-1.891) 0.005 67.7% 0.000
DLBCL (with rituximab) 5 753 1.495(1.084-2.062) 0.014 52.3% 0.078
DLBCL (without rituximab) 9 1835 1.456(0.951-2.23) 0,084 74.8% 0.000
MCL (total) 7 904 2.48(1.61-3.81) 0.000 85.6% 0.000
MCL (with rituximab) 3 581 1.981(1.099-3.569) 0.023 87.4% 0.000
MCL (without rituximab) 3 243 3.123(2.049-4.76) 0.000 21.8% 0.278
NK/TL 2 93 4.766(1.917-11.849) 0.001 0% 0.853